Cat. No. 4000
Chemical Name: N-[cis-4-[(4-Chlorophenyl)sulfonyl]
Biological Activityγ-secretase inhibitor; inhibits proteolytic cleavage of amyloid precursor protein (APP) over the Notch pathway. Reduces levels of Aβ in the brain (inhibits Aβ40 and Aβ42 in SH-SY5Y neuroblastoma cells with an IC50 of 0.65 nM); attenuates plaque deposition. Orally bioavailable.
Licensing InformationManufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Best et al (2006) In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat. J.Pharm.Exp.Ther. 317 786. PMID: 16443723.
Best et al (2007) The novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of Notch-related pathology in the Tg2576 mouse. J.Pharm.Exp.Ther. 320 552. PMID: 17099072.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MRK 560, supplier, MRK560, gamma-secretase, inhibitor, g-secretase, inhibitors, secretases
Find multiple products by catalog number
New Products in this Area
Non-peptide, competitive angiotensin-converting enzyme (ACE) inhibitorAprotinin
Competitive serine protease inhibitorTCID
Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor2-MPPA
Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailableE 64
Potent and irreversible cysteine protease inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.